Kura Oncology (NASDAQ:KURA) Trading Down 2.3%

Kura Oncology, Inc. (NASDAQ:KURA) shares were down 2.3% during mid-day trading on Tuesday . The company traded as low as $20.33 and last traded at $20.39. Approximately 12,316 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 952,298 shares. The stock had previously closed at $20.87.

Analyst Ratings Changes

Several research analysts have weighed in on KURA shares. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Stifel Nicolaus lowered their target price on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $30.60.

Kura Oncology Stock Up 0.5 %

The firm has a market cap of $1.54 billion, a PE ratio of -9.34 and a beta of 0.84. The company has a 50-day simple moving average of $20.30 and a 200-day simple moving average of $20.63. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the previous year, the firm posted ($0.53) EPS. The business’s revenue was up .0% compared to the same quarter last year. Analysts expect that Kura Oncology, Inc. will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of KURA. BVF Inc. IL grew its position in shares of Kura Oncology by 9.5% during the 4th quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after buying an additional 642,245 shares in the last quarter. Vanguard Group Inc. grew its holdings in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Kura Oncology by 10.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock worth $28,785,000 after buying an additional 197,530 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.